Initial Follow Up Results from the REP 301 Trial: Safety and Efficacy of REP 2139-Ca and Pegylated Interferon Alpha-2a in Caucasian Patients with Chronic HBV / HDV Co-infection

被引：0
|
作者：
Bazinet, Michel [1 ]
Pantea, Victor [2 ]
Cebotarescu, Valentin [2 ]
Cojuhari, Lilia [3 ]
Jimbei, Paulina [3 ]
Albrecht, Jeffrey [4 ]
Schmid, Peter [4 ]
Krawczyk, Adalbert [5 ]
Karimzadeh, Hadi [6 ]
Roggendorf, Michael [6 ]
Valliant, Andrew [1 ]
机构：
[1] Replicor Inc, Montreal, PQ, Canada
[2] N Testemitanu State Univ Med & Pharm, Dept Infect Dis, Kishinev, Moldova
[3] Toma Ciorba Infect Clin Hospita, Kishinev, Moldova
[4] Natl Genet Inst, Los Angeles, CA USA
[5] Univ Klinikum Essen, Inst Virol, Essen, Germany
[6] Tech Univ Munich, Inst Virol, Munich, Germany
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1848
引用
收藏
页码：912A / 912A
页数：1
相关论文
共 38 条
  • [21] Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia and Polycythemia Vera: Results after a Median 7-Year Follow-up of a Phase 2 Study
    Masarova, Lucia
    Verstovsek, Srdan
    Patel, Keyur P.
    Newberry, Kate J.
    Cortes, Jorge E.
    Borthakur, Gautam
    Konopleva, Marina
    Estrov, Zeev
    Kantarjian, Hagop M.
    BLOOD, 2015, 126 (23)
  • [22] Interim results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection
    Wedemeyer, Heiner
    Alexandrov, Alexander
    Bogomolov, Pavel
    Blank, Antje
    Bremer, Birgit
    Voronkova, Natalia
    Schoneweis, Katrin
    Raupach, Regina
    Lehmann, Patrick
    Darnedde, Martina
    Pathil, Anita
    Burhenne, Jurgen
    Haag, Mathias
    Schwab, Matthias
    Haefeli, Walter E.
    Urban, Stephan
    HEPATOLOGY, 2017, 66 : 20A - 21A
  • [23] Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection
    Wedemeyer, H.
    Bogomolov, P.
    Blank, A.
    Allweiss, L.
    Dandri-Petersen, M.
    Bremer, B.
    Voronkova, N.
    Schoeneweis, K.
    Pathil, A.
    Burhenne, J.
    Haag, M.
    Schwab, M.
    Haefeli, W. -E.
    Wiesch, J. S. Z.
    Alexandrov, A.
    Urban, S.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S3 - S3
  • [24] The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-a2b and ribavirin in patients with HBV/HCV co-infection
    Potthoff, A.
    Wedemeyer, H.
    Boecher, W. O.
    Berg, T.
    Zeuzem, S.
    Arnold, J.
    Spengler, U.
    Gruengreiff, K.
    Kaeser, T.
    Kassai, A.
    Schuchmann, M.
    Bergk, A.
    Forestier, N.
    Deterding, K.
    Manns, M. P.
    Trautwein, C.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S320 - S320
  • [25] LONG-TERM FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIAL OF ALPHA-2A INTERFERON (IFN) IN CHINESE PATIENTS WITH CHRONIC HEPATITIS-B VIRUS (HBV) INFECTION
    LOK, ASF
    LAI, CL
    LAU, JYN
    CHUNG, HT
    HEPATOLOGY, 1990, 12 (04) : 965 - 965
  • [26] The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection
    Potthoff, Andrej
    Wedemeyer, Heiner
    Boecher, Wulf O.
    Berg, Thomas
    Zeuzem, Stefan
    Arnold, Joachim
    Spengler, Ulrich
    Gruengreiw, Kurt
    Kaeser, Thomas
    Schuchmann, Marcus
    Bergk, Alexandra
    Forestier, Nicole
    Deterding, Katja
    Manns, Michael P.
    Trautwein, Christian
    JOURNAL OF HEPATOLOGY, 2008, 49 (05) : 688 - 694
  • [27] A Phase 2 Randomized Clinical Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda Monotherapy in Patients with Chronic Hepatitis Delta Virus Infection. Interim Results From the LIMT HDV Study
    Hamid, Saeed S.
    Etzion, Ohad
    Lurie, Yoav
    Bader, Nimrah
    Yardeni, David
    Channa, Saleh M.
    Mawani, Minaz
    Parkash, Om
    Martins, Eduardo B.
    Gane, Edward J.
    HEPATOLOGY, 2017, 66 : 496A - 496A
  • [28] Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit
    Covic, Adrian
    Maftei, Irinel-Doina
    Mardare, Nicoleta G. L.
    Ionita-Radu, Florentina
    Totolic, Camelia
    Tuta, Liliana
    Golea, Ovidiu
    Covic, Maria
    Volovat, Carmen
    Gusbeth-Tatomir, Paul
    Mircescu, Gabriel
    JOURNAL OF NEPHROLOGY, 2006, 19 (06) : 794 - 801
  • [29] SAFETY AND EFFICACY OF 10mg (HIGH-DOSE) BULEVIRTIDE (MYRCLUDEX B) IN COMBINATION WITH PEG-INTERFERON ALPHA 2a OR TENOFOVIR IN PATIENTS WITH CHRONIC HBV/HDV CO-INFECTION: WEEK 24 INTERIM RESULTS OF THE MYR203 EXTENSION STUDY.
    Wedemeyer, Heiner
    Schoeneweis, Katrin
    Bogomolov, Pavel
    Voronkova, Natalia
    Chulanov, Vladimir
    Stepanova, Tatyana
    Allweiss, Lena
    Dandri, Maura
    Ciesek, Sandra
    Dittmer, Ulf
    Haefeli, Walter E.
    Alexandrov, Alexander
    Urban, Stephan
    HEPATOLOGY, 2019, 70 : 58A - 59A
  • [30] SAFETY AND EFFICACY OF 2mg BULEVIRTIDE IN PATIENTS WITH CHRONIC HBV/HDV CO-INFECTION. FIRST REAL-WORLD RESULTS (FRENCH EARLY ACCESS PROGRAM).
    De Ledinghen, Victor
    Guyader, Dominique
    Metivier, Sophie
    Hilleret, Marie-Noelle
    Fontaine, Helene
    Roche, Bruno
    Carrie, Nathalie Ganne
    Alteroche, Louis D.
    Ratti, Veronique Loustaud
    Gervais, Anne
    Stern, Christiane
    Alric, Laurent
    Hubert, Isabelle Fouchard
    Asselah, Tarik
    Lacombe, Karine
    Zoulim, Fabien
    Dumortier, Jerome
    Franza, Anne Minello
    Lascoux-Combe, Caroline
    Muti, Leon
    Hourmand, Isabelle Ollivier
    Larrey, Dominique
    Leroy, Vincent
    Rosa, Isabelle
    Chas, Julie
    Heluwaert, Frederic
    Borentain, Patrick
    Mabile, Isabelle Archambeaud
    Prouvost-Keller, Bernard
    Ahmed, Si Nafa Si
    Roulot-Marullo, Dominique
    HEPATOLOGY, 2021, 74 : 16A - 17A
1234